Akhila Alapati1, Kerry Goetz2, John Suk1, Mili Navani1, Amani Al-Tarouti3, Thiran Jayasundera3, Santa J Tumminia4, Pauline Lee1, Radha Ayyagari1. 1. Shiley Eye Center, University of California-San Diego, La Jolla, California, United States. 2. Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States. 3. W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States. 4. Office of the Director, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Abstract
PURPOSE: To analyze the genetic test results of probands referred to eyeGENE with a diagnosis of hereditary maculopathy. METHODS: Patients with Best macular dystrophy (BMD), Doyne honeycomb retinal dystrophy (DHRD), Sorsby fundus dystrophy (SFD), or late-onset retinal degeneration (LORD) were screened for mutations in BEST1, EFEMP1, TIMP3, and CTRP5, respectively. Patients with pattern dystrophy (PD) were screened for mutations in PRPH2, BEST1, ELOVL4, CTRP5, and ABCA4; patients with cone-rod dystrophy (CRD) were screened for mutations in CRX, ABCA4, PRPH2, ELOVL4, and the c.2513G>A p.Arg838His variant in GUCY2D. Mutation analysis was performed by dideoxy sequencing. Impact of novel variants was evaluated using the computational tool PolyPhen. RESULTS: Among the 213 unrelated patients, 38 had BMD, 26 DHRD, 74 PD, 8 SFD, 6 LORD, and 54 CRD; six had both PD and BMD, and one had no specific clinical diagnosis. BEST1 variants were identified in 25 BMD patients, five with novel variants of unknown significance (VUS). Among the five patients with VUS, one was diagnosed with both BMD and PD. A novel EFEMP1 variant was identified in one DHRD patient. TIMP3 novel variants were found in two SFD patients, PRPH2 variants in 14 PD patients, ABCA4 variants in four PD patients, and p.Arg838His GUCY2D mutation in six patients diagnosed with dominant CRD; one patient additionally had a CRX VUS. ABCA4 mutations were identified in 15 patients with recessive CRD. CONCLUSIONS: Of the 213 samples, 55 patients (26%) had known causative mutations, and 13 (6%) patients had a VUS that was possibly pathogenic. Overall, selective screening for mutations in BEST1, PRPH2, and ABCA4 would likely yield the highest success rate in identifying the genetic basis for macular dystrophy phenotypes. Because of the overlap in phenotypes between BMD and PD, it would be beneficial to screen genes associated with both diseases. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To analyze the genetic test results of probands referred to eyeGENE with a diagnosis of hereditary maculopathy. METHODS:Patients with Best macular dystrophy (BMD), Doyne honeycombretinal dystrophy (DHRD), Sorsby fundus dystrophy (SFD), or late-onset retinal degeneration (LORD) were screened for mutations in BEST1, EFEMP1, TIMP3, and CTRP5, respectively. Patients with pattern dystrophy (PD) were screened for mutations in PRPH2, BEST1, ELOVL4, CTRP5, and ABCA4; patients with cone-rod dystrophy (CRD) were screened for mutations in CRX, ABCA4, PRPH2, ELOVL4, and the c.2513G>A p.Arg838His variant in GUCY2D. Mutation analysis was performed by dideoxy sequencing. Impact of novel variants was evaluated using the computational tool PolyPhen. RESULTS: Among the 213 unrelated patients, 38 had BMD, 26 DHRD, 74 PD, 8 SFD, 6 LORD, and 54 CRD; six had both PD and BMD, and one had no specific clinical diagnosis. BEST1 variants were identified in 25 BMDpatients, five with novel variants of unknown significance (VUS). Among the five patients with VUS, one was diagnosed with both BMD and PD. A novel EFEMP1 variant was identified in one DHRDpatient. TIMP3 novel variants were found in two SFDpatients, PRPH2 variants in 14 PDpatients, ABCA4 variants in four PDpatients, and p.Arg838HisGUCY2D mutation in six patients diagnosed with dominant CRD; one patient additionally had a CRX VUS. ABCA4 mutations were identified in 15 patients with recessive CRD. CONCLUSIONS: Of the 213 samples, 55 patients (26%) had known causative mutations, and 13 (6%) patients had a VUS that was possibly pathogenic. Overall, selective screening for mutations in BEST1, PRPH2, and ABCA4 would likely yield the highest success rate in identifying the genetic basis for macular dystrophy phenotypes. Because of the overlap in phenotypes between BMD and PD, it would be beneficial to screen genes associated with both diseases. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: K Gregory-Evans; R E Kelsell; C Y Gregory-Evans; S M Downes; F W Fitzke; G E Holder; M Simunovic; J D Mollon; R Taylor; D M Hunt; A C Bird; A T Moore Journal: Ophthalmology Date: 2000-01 Impact factor: 12.079
Authors: G H Travis; L Christerson; P E Danielson; I Klisak; R S Sparkes; L B Hahn; T P Dryja; J G Sutcliffe Journal: Genomics Date: 1991-07 Impact factor: 5.736
Authors: C A Kuntz; S G Jacobson; A V Cideciyan; Z Y Li; E M Stone; D Possin; A H Milam Journal: Invest Ophthalmol Vis Sci Date: 1996-08 Impact factor: 4.799
Authors: K Jaakson; J Zernant; M Külm; A Hutchinson; N Tonisson; D Glavac; M Ravnik-Glavac; M Hawlina; M R Meltzer; R C Caruso; F Testa; A Maugeri; C B Hoyng; P Gouras; F Simonelli; R A Lewis; J R Lupski; F P M Cremers; R Allikmets Journal: Hum Mutat Date: 2003-11 Impact factor: 4.878
Authors: Caroline Hayward; Xinhua Shu; Artur V Cideciyan; Alan Lennon; Perdita Barran; Sepideh Zareparsi; Lindsay Sawyer; Grace Hendry; Baljean Dhillon; Ann H Milam; Philip J Luthert; Anand Swaroop; Nicholas D Hastie; Samuel G Jacobson; Alan F Wright Journal: Hum Mol Genet Date: 2003-08-27 Impact factor: 6.150
Authors: Hema L Ramkumar; Harini V Gudiseva; Kameron T Kishaba; John J Suk; Rohan Verma; Keerti Tadimeti; John A Thorson; Radha Ayyagari Journal: Genet Test Mol Biomarkers Date: 2016-12-22
Authors: Manon H C A Peeters; Mubeen Khan; Anoek A M B Rooijakkers; Timo Mulders; Lonneke Haer-Wigman; Camiel J F Boon; Caroline C W Klaver; L Ingeborgh van den Born; Carel B Hoyng; Frans P M Cremers; Anneke I den Hollander; Claire-Marie Dhaenens; Rob W J Collin Journal: Hum Mutat Date: 2021-09-20 Impact factor: 4.700
Authors: Morton F Goldberg; Scott McLeod; Mark Tso; Kirk Packo; Malia Edwards; Imran A Bhutto; Rajkumar Baldeosingh; Charles Eberhart; Bernhard H F Weber; Gerard A Lutty Journal: Ophthalmol Retina Date: 2018-04